China has become the first country to approve a globally developed drug for a rare disease ahead of regulatory authorities in the United States, Japan, and Europe, marking a significant milestone in the nation's biopharmaceutical sector. The approval was announced by the National Medical Products Administration (NMPA) on Tuesday.

The drug, developed by the Japanese pharmaceutical company Takeda, is intended to treat narcolepsy type 1 in patients aged 16 and older. Narcolepsy type 1 is a chronic neurological condition characterized by excessive daytime sleepiness and sudden muscle weakness triggered by strong emotions such as laughter or anger. The specific medication—Takeda’s TAK-861—had its marketing application accepted for review by the NMPA in January and was granted priority review status within the same month.

Xu Xiaoqiang, head of chemical drugs registration at the NMPA, described the approval as a "historic breakthrough" for China in the realm of first-in-class drug innovation. He highlighted that Chinese patients participated in the international clinical trials from the outset, which contributed to the country’s ability to grant earlier approval than other regulators worldwide.

While the drug’s name was not disclosed in official reports, it has received fast-track designation in the United States and orphan-drug designation in Japan and the European Union. Orphan-drug status provides incentives such as tax relief and market exclusivity to encourage the development of treatments for rare diseases.

This regulatory milestone aligns with China’s broader strategic emphasis on biotechnology as a key growth sector. The industry was highlighted as a “pillar” sector in the government’s work report delivered to the national legislature in March. The country has witnessed a record number of cross-border licensing agreements between domestic biotech companies and multinational pharmaceutical corporations, reflecting increased collaboration and innovation.

In the first half of this year, China approved 38 new innovative drugs, with the majority originating from domestic developers. This represents a departure from past trends when foreign therapies usually reached Chinese patients several years after their initial approval in markets such as the United States, Japan, or Europe—a lag noted in a 2022 study published in Therapeutic Innovation & Regulatory Science.

The accelerated review and approval process for TAK-861 underscores China’s evolving position in the global pharmaceutical landscape, moving from a follower to a more proactive participant in novel drug development and access.